Homozygous deletions of cadherin genes in chondrosarcoma-an array comparative genomic hybridization study

Cancer Genetics

Volumn 205, Issue 11, 2012, Pages 588-593

  Niini, Tarja ^a   Scheinin, Ilari ^a,b,c   Lahti, Leo ^a,d   Savola, Suvi ^a   Mertens, Fredrik ^e   Hollmén, Jaakko ^d   Böhling, Tom ^a   Kivioja, Aarne ^a   Nord, Karolin H ^e   Knuutila, Sakari ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF HELSINKI   (Finland)

^d AALTO UNIVERSITY   (Finland)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Array comparative genomic hybridization; Cadherin gene; Chondrosarcoma; MTAP; RB1 signaling pathway

Indexed keywords

CADHERIN; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR D; TRANSCRIPTION FACTOR E2F3;

ARRAY COMPARATIVE GENOMIC HYBRIDIZATION; ARTICLE; CADHERIN GENE; CDH19 GENE; CDH4 GENE; CDH7 GENE; CDK6 GENE; CDKN2A GENE; CHONDROSARCOMA; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; DNA MICROARRAY; E2F3 GENE; EXT1 GENE; EXT2 GENE; GENE AMPLIFICATION; GENE DELETION; GENE IDENTIFICATION; GENETIC GAIN; HETEROZYGOSITY LOSS; HOMOZYGOSITY; HOMOZYGOSITY LOSS; HUMAN; HUMAN TISSUE; KIT GENE; MTAP GENE; ONCOGENE MYC; PDGFD GENE; PDGFRA GENE; PRIORITY JOURNAL; RB1 GENE; TUMOR SUPPRESSOR GENE;

BONE NEOPLASMS; CADHERINS; CHONDROSARCOMA; CHROMOSOME ABERRATIONS; COMPARATIVE GENOMIC HYBRIDIZATION; DNA, NEOPLASM; FEMALE; GENE AMPLIFICATION; GENE DELETION; HUMANS; MALE; PURINE-NUCLEOSIDE PHOSPHORYLASE; TUMOR SUPPRESSOR PROTEINS;

EID: 84869399137     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2012.09.007     Document Type: Article

References (39)

1. Bertoni F., Bacchini P., Hogendoorn P.C.W. Chondrosarcoma. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone 2002, 247. IARCPress, Lyon, France. C.D.M. Fletcher, K.K. Unni, F. Mertens (Eds.).
2. Bovee J.V., Hogendoorn P.C., Wunder J.S., et al. Cartilage tumours and bone development: molecular pathology and possible therapeutic targets. Nat Rev Cancer 2010, 10:481-488.
3. Rozeman L.B., Cleton-Jansen A.M., Hogendoorn P.C. Pathology of primary malignant bone and cartilage tumours. Int Orthop 2006, 30:437-444.
4. Bovee J.V., Hogendoorn P.C. Molecular pathology of sarcomas: concepts and clinical implications. Virchows Arch 2010, 456:193-199.
5. Hameetman L., Szuhai K., Yavas A., et al. The role of EXT1 in nonhereditary osteochondroma: identification of homozygous deletions. J Natl Cancer Inst 2007, 99:396-406.
6. Zuntini M., Pedrini E., Parra A., et al. Genetic models of osteochondroma onset and neoplastic progression: evidence for mechanisms alternative to EXT genes inactivation. Oncogene 2010, 29:3827-3834.
7. Gelderblom H., Hogendoorn P.C., Dijkstra S.D., et al. The clinical approach towards chondrosarcoma. Oncologist 2008, 13:320-329.
8. Mandahl N., Gustafson P., Mertens F., et al. Cytogenetic aberrations and their prognostic impact in chondrosarcoma. Genes Chromosomes Cancer 2002, 33:188-200.
9. Larramendy M.L., Mandahl N., Mertens F., et al. Clinical significance of genetic imbalances revealed by comparative genomic hybridization in chondrosarcomas. Hum Pathol 1999, 30:1247-1253.
10. Hallor K.H., Staaf J., Bovee J.V., et al. Genomic profiling of chondrosarcoma: chromosomal patterns in central and peripheral tumors. Clin Cancer Res 2009, 15:2685-2694.
11. Rozeman L.B., Szuhai K., Schrage Y.M., et al. Array-comparative genomic hybridization of central chondrosarcoma: identification of ribosomal protein S6 and cyclin-dependent kinase 4 as candidate target genes for genomic aberrations. Cancer 2006, 107:380-388.
12. Schrage Y.M., Lam S., Jochemsen A.G., et al. Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth in vitro. J Cell Mol Med 2009, 13:2843-2852.
13. Hameed M., Ulger C., Yasar D., et al. Genome profiling of chondrosarcoma using oligonucleotide array-based comparative genomic hybridization. Cancer Genet Cytogenet 2009, 192:56-59.
14. Scheinin I., Myllykangas S., Borze I., et al. CanGEM: mining gene copy number changes in cancer. Nucleic Acids Res 2008, 36:D830-D835.
15. Schrage Y.M., Hameetman L., Szuhai K., et al. Aberrant heparan sulfate proteoglycan localization, despite normal exostosin, in central chondrosarcoma. Am J Pathol 2009, 174:979-988.
16. de Andrea C.E., Reijnders C.M., Kroon H.M., et al. Secondary peripheral chondrosarcoma evolving from osteochondroma as a result of outgrowth of cells with functional EXT. Oncogene 2012, 31:1095-1104.
17. Sabah M., Cummins R., Leader M., et al. Aberrant expression of the Rb pathway proteins in soft tissue sarcomas. Appl Immunohistochem Mol Morphol 2006, 14:397-403.
18. Grasemann C., Gratias S., Stephan H., et al. Gains and overexpression identify DEK and E2F3 as targets of chromosome 6p gains in retinoblastoma. Oncogene 2005, 24:6441-6449.
19. Orlic M., Spencer C.E., Wang L., et al. Expression analysis of 6p22 genomic gain in retinoblastoma. Genes Chromosomes Cancer 2006, 45:72-82.
20. Wikenheiser-Brokamp K.A. Retinoblastoma regulatory pathway in lung cancer. Curr Mol Med 2006, 6:783-793.
21. Cooper C.S., Nicholson A.G., Foster C., et al. Nuclear overexpression of the E2F3 transcription factor in human lung cancer. Lung Cancer 2006, 54:155-162.
22. Feber A., Clark J., Goodwin G., et al. Amplification and overexpression of E2F3 in human bladder cancer. Oncogene 2004, 23:1627-1630.
23. Hurst C.D., Tomlinson D.C., Williams S.V., et al. Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification. Oncogene 2008, 27:2716-2727.
24. Oeggerli M., Tomovska S., Schraml P., et al. E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene 2004, 23:5616-5623.
25. Bertino J.R., Waud W.R., Parker W.B., et al. Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: Current strategies. Cancer Biol Ther 2011, 11:627-632.
26. Chow W.A., Bedell V., Gaytan P., et al. Methylthioadenosine phosphorylase gene deletions are frequently detected by fluorescence in situ hybridization in conventional chondrosarcomas. Cancer Genet Cytogenet 2006, 166:95-100.
27. Camacho-Vanegas O., Camacho S.C., Till J., et al. Primate genome gain and loss: a bone dysplasia, muscular dystrophy, and bone cancer syndrome resulting from mutated retroviral-derived MTAP transcripts. Am J Hum Genet 2012, 90:614-627.
28. Huang H.Y., Li S.H., Yu S.C., et al. Homozygous deletion of MTAP gene as a poor prognosticator in gastrointestinal stromal tumors. Clin Cancer Res 2009, 15:6963-6972.
29. Kim J., Kim M.A., Min S.Y., et al. Downregulation of methylthioadenosin phosphorylase by homozygous deletion in gastric carcinoma. Genes Chromosomes Cancer 2011, 50:421-433.
30. Schmid M., Malicki D., Nobori T., et al. Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16INK4A (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC). Oncogene 1998, 17:2669-2675.
31. Kadariya Y., Yin B., Tang B., et al. Mice heterozygous for germ-line mutations in methylthioadenosine phosphorylase (MTAP) die prematurely of T-cell lymphoma. Cancer Res 2009, 69:5961-5969.
32. Christopher S.A., Diegelman P., Porter C.W., et al. Methylthioadenosine phosphorylase, a gene frequently codeleted with p16(cdkN2a/ARF), acts as a tumor suppressor in a breast cancer cell line. Cancer Res 2002, 62:6639-6644.
33. Behrmann I., Wallner S., Komyod W., et al. Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma. Am J Pathol 2003, 163:683-690.
34. Marce S., Balague O., Colomo L., et al. Lack of methylthioadenosine phosphorylase expression in mantle cell lymphoma is associated with shorter survival: implications for a potential targeted therapy. Clin Cancer Res 2006, 12:3754-3761.
35. van Beerendonk H.M., Rozeman L.B., Taminiau A.H., et al. Molecular analysis of the INK4A/INK4A-ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression. J Pathol 2004, 202:359-366.
36. Ishii M., Nakazawa K., Wada H., et al. Methylthioadenosine phosphorylase gene is silenced by promoter hypermethylation in human lymphoma cell line DHL-9: another mechanism of enzyme deficiency. Int J Oncol 2005, 26:985-991.
37. Berx G., van Roy F. Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol 2009, 1:a003129.
38. Mansouri M., Rose P.P., Moses A.V., et al. Remodeling of endothelial adherens junctions by Kaposi's sarcoma-associated herpesvirus. J Virol 2008, 82:9615-9628.
39. Qian L.W., Greene W., Ye F., et al. Kaposi's sarcoma-associated herpesvirus disrupts adherens junctions and increases endothelial permeability by inducing degradation of VE-cadherin. J Virol 2008, 82:11902-11912.